Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vigonvita Life Sciences CoHKSE:02630 +5.32%8 Current Ratio is 1.07 as of Dec. 2025, which is 84% above its 10-year median of 0.58. GuruFocus rates HKSE:02630 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 999 Drug Manufacturers companies, Vigonvita Life Sciences Co ranks worse than 80.98% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vigonvita Life Sciences Co's current ratio for the quarter that ended in Dec. 2025 was 1.07.
Vigonvita Life Sciences Co has a current ratio of 1.07. It generally indicates good short-term financial strength.
The historical rank and industry rank for Vigonvita Life Sciences Co's Current Ratio or its related term are showing as below:
HKSE:02630'
s Current Ratio Range Over the Past 10 Years
Min: 0.49 Med: 0.58 Max: 1.07
Current: 1.07
During the past 3 years, Vigonvita Life Sciences Co's highest Current Ratio was 1.07. The lowest was 0.49. And the median was 0.58.
HKSE:02630's Current Ratio is ranked worse than 80.98% of 999
companies
in the Drug Manufacturers industry
Industry Median: 2
vs HKSE:02630: 1.07
Vigonvita Life Sciences Co (HKSE:02630) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Vigonvita Life Sciences Co Current Ratio Related Terms
Vigonvita Life Sciences Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co Current Ratio Chart
Vigonvita Life Sciences Co Annual Data
Trend
Dec23
Dec24
Dec25
Current Ratio
0.58
0.49
1.07
Vigonvita Life Sciences Co Semi-Annual Data
Dec23
Dec24
Dec25
Current Ratio
0.58
0.49
1.07
HKSE:02630 vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Vigonvita Life Sciences Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vigonvita Life Sciences Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vigonvita Life Sciences Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Vigonvita Life Sciences Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co (HKSE:02630) has a Current Ratio of 1.07 as of Dec. 2025. This is 84% above median its historical median of 0.58. Over the past decade, Vigonvita Life Sciences Co's Current Ratio has ranged from 0.49 to 1.07. According to the industry distribution chart, Vigonvita Life Sciences Co ranks #809 out of 999 companies in the Drug Manufacturers industry, placing it in the top 81%.
Is Vigonvita Life Sciences Co's Current Ratio too high?
Vigonvita Life Sciences Co's current Current Ratio of 1.07 is 84% above median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 1.07. The Drug Manufacturers industry median Current Ratio is 2.00. Vigonvita Life Sciences Co's value of 1.07 is 46.5% below this industry median. Based on the distribution chart, Vigonvita Life Sciences Co ranks #809 out of 999 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Vigonvita Life Sciences Co ranks #809 out of 999 companies for Current Ratio. This places Vigonvita Life Sciences Co in the lower half of its industry. The industry median Current Ratio is 2.00. Vigonvita Life Sciences Co's value of 1.07 is 46.5% below this benchmark. Historically, Vigonvita Life Sciences Co's own Current Ratio has ranged from 0.49 to 1.07 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 2.00, Vigonvita Life Sciences Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vigonvita Life Sciences Co's current Current Ratio of 1.07 is 46.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vigonvita Life Sciences Co's current Current Ratio is 1.07, which is 84% above median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current Current Ratio of 1.07. The current Current Ratio is 1.07, which is 84% above median its 10-year median of 0.58 and 46.5% below the Drug Manufacturers industry median of 2.00. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current Current Ratio is 1.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score
Get the complete analysis for HKSE:02630
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02630 has been successfully added to your 
